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become attractive alternatives to conventional 
surgical treatment of severe AS in high-risk pa-
tients.4,5 TAVI is considered a safe and effective 
treatment modality in elderly patients who are 
not eligible for surgery or who carry an unac-
ceptably high perioperative risk to undergo sur-
gical treatment.6-9 TAVI is associated with faster 
INTRODUCTION Aortic stenosis (AS) is the most 
common type of acquired valvular heart disease.1,2 
Its incidence increases with age, and from 3% to 
9% of adults over 75 years of age develop AS.3
Transcatheter aortic valve implantation (TAVI) 
and minimally invasive aortic valve replacement 
(minithoracotomy and ministernotomy) have 
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INTRODUCTION Transcatheter aortic valve implantation (TAVI) and minimally invasive aortic valve re-
placement (minithoracotomy and ministernotomy) have become a valuable alternative to conventional 
surgical treatment of severe aortic stenosis (AS) in high-risk patients.
OBJECTIVES The aim of the study was to evaluate long-term results and complications in patients 
with symptomatic AS treated with TAVI, surgical aortic valve replacement (SAVR), minithoracotomy, 
or ministernotomy.
PATIENTS AND METHODS A total of 173 patients with symptomatic AS were enrolled to the study be-
tween the years 2011 and 2013. Propensity scores were calculated for TAVI and each surgical method 
separately. Differences in clinical outcomes between patients treated with TAVI and those treated with 
surgical methods were adjusted for propensity scores using a logistic regression analysis and presented 
as adjusted odds ratios with 95% confidence intrervals.
RESULTS A median follow-up was 583.5 days (interquartile range, 298–736 days). Before aortic valve 
replacement (AVR), no significant differences in ejection fraction (EF) were observed between the groups. 
At 1 week after AVR, mean EF values were significantly higher in patients after TAVI in comparison 
with the other groups (TAVI, 50.2% ±13.1%; minithoracotomy, 44.1% ±13.4%; ministernotomy, 37.8% 
±12.8%; SAVR, 40.3% ±12.5%; P = 0.001). There were no differences in the longest available follow-up 
mortality between the analyzed groups (P = 0.8). To our best knowledge, this is the first study compar-
ing minithoracotomy, ministernotomy, and SAVR with TAVI in terms of long-term outcomes such as the 
longest available follow-up mortality, left ventricular (LV) function, complications after the procedure, 
and conduction disturbances and arrhythmias after the procedure.
CONCULSIONS Patients undergoing TAVI show more beneficial long-term outcomes in comparison with 
patients undergoing minithoracotomy, ministernotomy, and SAVR and do not differ in terms of the longest 
available follow-up mortality. TAVI seems to have a more favorable effect on LV function and an increase 
in EF in comparison with the surgical methods.
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The analysis was done in the “intention-to-treat” 
manner. The protocol was approved by the local 
ethics committee. The study was conducted in 
accordance with the ethical principles for clini-
cal research based on the Declaration of Helsin-
ki with subsequent amendments. 
Statistical analysis Standard descriptive sta-
tistical methods were used in the anal ysis. The 
normality of the data was assessed with the 
Shapiro–Wilk test. Quantitative variables were 
described using means and standard deviations 
or medians and interquartile ranges. Categorical 
variables were presented as percentages. A direct 
comparison between the groups was done using 
the χ2 test for categorical variables. One-way anal-
ysis of variance with the post hoc Tukey test (for 
normal distribution with equal variance between 
the groups) or the Kruskal–Wallis test (for non-
normally distributed data) was applied for quan-
titative variables. The effect of using TAVI versus 
surgical methods on mortality and other clinical 
outcome parameters was presented as odds ra-
tios (ORs) and 95% confidence intervals (CIs). 
To adjust for possible selection bias, a propensi-
ty score14 for each individual’s likelihood of be-
ing treated with TAVI was calculated based on 
the following variables: sex, age, previous percu-
taneous coronary intervention, previous myocar-
dial infarction, peripheral arterial disease, carot-
id stenosis, and logistic EuroSCORE. Propensity 
scores were calculated for individuals compari-
sons between TAVI and minithoracotomy, TAVI 
and ministernotomy, and TAVI and SAVR. Dif-
ferences in clinical outcomes between patients 
treated with TAVI compared with those treated 
with surgical methods were adjusted for the pro-
pensity scores using a logistic regression analysis 
and presented as adjusted ORs with 95% CIs. The 
level of statistical significance was set at a P val-
ue of 0.05 or lower. All analyses were conducted 
with the STATISTICA v 10 software (StatSoft, 
Inc., Kraków, Poland).
RESULTS TAVI was performed in 39 patients 
(22.5%); ministernotomy, in 44 patients (25.5%); 
minithoracotomy, in 50 patients (29%); and 
SAVR, in 40 patients (23%). All procedures were 
performed electively. TAVI, SAVR, and minister-
notomy were performed successfully in all cases. 
The type of the procedure was changed only in 1 
patient, initially scheduled for minithoracotomy 
(successful in 98% of the cases), but during the in-
tervention, it was changed to SAVR. The Edwards 
SAPIEN XT valve was implanted in 31 patients 
(79%), while the Medtronic CoreValve—in 8 pa-
tients (21%) allocated to the TAVI group. Trans-
femoral access was used in all patients undergoing 
TAVI. In contrast to other groups, patients  un-
dergoing TAVI were less frequently male (35.9%, 
66%, 45.4%, and 55% for TAVI, minithoracot-
omy, ministernotomy, and SAVR, respectively; 
P = 0.03) and were significantly older (medican, 
80 years [range, 73–83 years], 63 [54–73], 67 
recov ery and allows for earlier ambulation in com-
parison with conventional surgery.10 The superi-
ority of TAVI over medical therapy has been re-
cently established by the PARTNER trial, and pre-
liminary randomized data confirmed that TAVI 
is noninferior to surgical aortic valve replace-
ment (SAVR) in terms of safety and effective-
ness.11 The clinical benefits of the above aortic 
valve replacement (AVR) treatment options have 
not been widely investigated. Therefore, the aim 
of this study was to evaluate long-term results in 
patients with symptomatic AS and treated with 
TAVI (using transfemoral access), ministernoto-
my, minithoracotomy, or SAVR.
PATIENTS AND METHODS This report represents 
a comparative retrospective 2-center registry. The 
study group consisted of 173 consecutive patients 
with severe symptomatic AS admitted from Jan-
uary 1, 2011, to December 31, 2013, to the 2nd 
Department of Cardiology and Cardiovascular 
Interventions and Department of Cardiovascu-
lar Surgery and Transplantology of Jagiellonian 
University Medical College in Kraków, Poland. 
A preprocedural assessment of the included 
patients involved transthoracic and transesoph-
ageal echocardiography, carotid ultrasonography, 
spirometry, coronary angiography, and evaluation 
of peripheral access sites by arterial angiography 
or computed tomography angiography. Individual 
patient selection involved the assessment of risk 
level as well as feasibility and safety of the proce-
dure. All patients were evaluated by a dedicated 
multidisciplinary heart team consisting of cardiac 
surgeons, interventional cardiologists, anesthesi-
ologists, and radiologists expert in cardiovascular 
imag ing. Clinical decision making was based on 
a multimodality screening assessment including 
the evaluation of surgical risk by logistic EuroS-
CORE and EuroSCORE II.12 Additional risk crite-
ria were porcelain aorta, advanced liver cirrhosis, 
severe neurological impairment, and frailty based 
on the physician’s judgment.12 
After the assessment by the multidisciplinary 
heart team, patients were allocated to 4 types of 
AS treatment (transfemoral TAVI, ministernot-
omy, minithoracotomy, or SAVR). To avoid oper-
ator-related influence on the outcome, all proce-
dures were performed by the same team of expe-
rienced cardiac surgeons (SAVR, ministernotomy, 
minithoracotomy) or interventional cardiologists 
with cardiac surgeons (transfemoral TAVI). Ejec-
tion fraction (EF) was measured on the day of hos-
pital admission, on the day of valve replacement 
after the procedure, and 1 week after the proce-
dure. The definitions of complications were used 
according to the Valve Academic Research Con-
sortium guidelines (VARC-2).13 Adverse events 
were assessed at regular clinical follow-up visits 
at the hospital or by a standardized telephone in-
terview. Medical history was systematically tak-
en from all patients with suspected or confirmed 
events. Follow-up was performed perioperative-
ly and 6, 12, and 24 months after the procedure. 
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minithoracotomy, ministernotomy, and SAVR, 
respectively; P = 0.008). 
There were no significant differences between 
the groups in terms of previous carotid artery dis-
ease (P = 0.08), previous myocardial infarction 
(P = 0.9), previous carotid artery stenting (P = 
0.31), blood transfusions during hospitalization 
(P = 0.5), complications during the procedure (P = 
0.06), arrhythmias during the procedure (P = 0.5), 
and sudden cardiac arrest during the procedure 
(P = 0.2). Exercise tolerance was measured using 
the New York Heart Association (NYHA)classi-
fication. The results at baseline and 1 week after 
the treatment are presented in TABLE 1. 
The median follow-up of all patients was 583.5 
days (range, 298–736 days). There were no differ-
ences between the groups in periprocedural and 
in-hospital mortality rates or in 30-day, 6-month, 
1-year, and total mortality (TABLE 2). A relative 
risk of total mortality after adjustment for the 
EuroSCORE, logEuroSCORE, EuroSCORE II, as 
well as age and sex was calculated for the TAVI 
and surgical groups using the logistic regresion 
analysis (TABLE 3). After adjustment for propen-
sity scores using the logistic regresion analysis, 
patients in the TAVI group seemed to have rath-
er lower total mortality in comparison with the 
surgical groups, but the difference was not signif-
icant (TABLE 3). Complications after the procedure 
are presented in TABLE 4. The measurements of EF 
at baseline, after the procedure, and 1 week after 
the procedure are presented in FIGURE 1. The rate 
of complications after the procedure and clinical 
[57–77], and 69.5 [58–75] for TAVI, minithora-
cotomy, ministernotomy, and SAVR, respectively; 
P = 0.00001). The TAVI group was at higher peri-
procedural risk of major complications (EuroS-
CORE: median, 8 points [range, 7–10 points], 
2 [2–5], 4 [2–6], and 5.5 [3–6] for TAVI, mini-
thoracotomy, ministernotomy, and SAVR, re-
spectively; P = 0.00001; logEuroSCORE: medi-
an, 9.5% [range, 7%–14%], 2.7% [1.8%–3.8%], 
4% [2.2%–7%], and 4.5% [2.3%–6.6%] for TAVI, 
minithoracotomy, ministernotomy, and SAVR, re-
spectively; P = 0.00001; EuroSCORE II: medican, 
3.4% [range, 1.8%–5.4%], 1% [0.7%–1.4%], 1.2% 
[0.9%–1.6%], and 1.3% [0.8%–2.3%] for TAVI, 
minithoracotomy, ministernotomy, and SAVR, 
respectively; P = 0.00001). Patients treated with 
TAVI had a significantly shorter time of the pro-
cedure (121.5 ±43 min vs 267.8 ±73 min vs 237.6 
±31 min vs 214 ±41 min for TAVI, minithoracoto-
my, ministernotomy, and SAVR, respectively; P = 
0.00001) and lower blood loss (15 ±43 ml, 253.6 
±284.37 ml, 280.9 ±145.6 ml, and 232 ±117.8 ml 
for TAVI, minithoracotomy, ministernotomy, and 
SAVR, respectively; P = 0.00001). Patients allocat-
ed to TAVI underwent significantly more percu-
taneous transluminal angioplasties (10.3%, 0%, 
0%, and 0% for TAVI, minithoracotomy, minis-
ternotomy, and SAVR, respectively; P = 0.003), 
percutaneous coronary interventions (35.9%, 
10%, 11.4%, and 10% for TAVI, minithoracoto-
my, ministernotomy, and SAVR, respectively; P 
= 0.002), and coronary artery bypass grafting 
procedures (15.4%, 0%, 2.3%, and 5% for TAVI, 
TABLE 1 Exercise tolerance measured according to the New York Heart Association classification at baseline and 1 week after treatment
NYHA class TAVI (n = 39) MT (n = 50) MS (n = 44) SAVR (n = 40) P value
at baseline I 3.3% 10.5% 13.3% 17.2% 0.0006
II 22.6% 57.9% 60% 27.6%
III 54.8% 31.6% 26.7% 34.5%
IV 19.3% 0% 0% 20.7%
at 1 week I 78.1% 35.3% 52.8% 56.3% 0.03
II 18.8% 47.1% 27.8% 28.1%
III 3.1% 17.6% 19.4% 15.6%
IV 0% 0% 0% 0%
Abbreviations: MS, ministernotomy; MT, minithoracotomy; NYHA, New York Heart Association; SAVR, surgical aortic valve replacement;  
TAVI, transcatheter aortic valve implantation
TABLE 2 Mortality in the study groups
Variable TAVI (n = 39) MT (n = 50) MS (n = 44) SAVR (n = 40) P value
periprocedural mortality 0% 0% 2.3% 2.5% 0.5
in-hospital mortality 5.1% 2.0% 2.3% 2.5% 0.5
30-day mortality 7.7% 2.0% 2.5% 7.5% 0.4
6-month mortality 10.3% 6.0% 2.5% 7.5% 0.6
1-year mortality 10.3% 8.0% 2.5% 7.5% 0.7
longest available follow-up 
mortality
10.3% 8.0% 6.8% 7.5% 0.8
Abbreviations: see TABLE 1
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on left ventricular (LV) function. Complications, 
conduction disturbances, and arrhythmias after 
the procedure were significantly more often re-
ported after TAVI in comparison with minitho-
racotomy and ministernotomy, while there were 
no differences between TAVI and SAVR. To the 
best of our knowledge, this is the first study com-
paring minithoracotomy, ministernotomy, and 
SAVR with TAVI in terms of clinical results such 
as the longest available follow-up mortality, LV 
function, complications after the procedure, and 
conduction disturbances and arrhythmias after 
the procedure.
outcomes for TAVI vs surgical options in the sub-
groups of patients matched using the propensity 
score are presented in TABLE 5. Laboratory results 
are presented in TABLE 6.
DISCUSSION Our study revelead no differences 
in the longest available follow-up mortality be-
tween patients undergoing TAVI in comparison 
with those subject to surgical methods such as 
minithoracotomy, ministernotomy, and SAVR. 
EF 1 week after the procedure was significantly 
higher in patients undergoing TAVI in compar-
ison with those undergoing surgical treatment; 
therefore, TAVI seems to have a favorable effect 
TABLE 3 Comparison between unadjusted and adjusted odds ratios for all-cause mortality at the longest available follow-up between the study 
groups
Odds ratio TAVI vs MT P valuea TAVI vs MS P valueb TAVI vs SAVR P valuec
unadjusted 1.3 (0.3–5.6) 0.7 1.6 (0.3–7.5) 0.6 1.4 (0.3–6.8) 0.7
adjusted for EuroSCORE, points 0.5 (0.06–3.3) 0.4 0.9 (0.1–5.5) 0.9 1.5 (0.3–9.2) 0.6
logEuroSCORE, % 0.9 (0.2–5.2) 0.9 1.2 (0.2–7.5) 0.9 1.2 (0.2–7.1) 0.8
EuroSCORE II, % 1.4 (0.3–7.1) 0.7 1.8 (0.3–0.2) 0.5 1.3 (0.3–7) 0.7
age/sex 0.5 (0.08–2.6) 0.4 0.5 (0.08–3.1) 0.5 0.5 (0.07–3.8) 0.5
propensity score 0.4 (0.04–3.3) 0.4 0.3 (0.03–1.9) 0.6 0.3 (0.04–2.8) 0.3
Data presented as odds ratio with 95% confidence interval.
a TAVI vs MT;  b TAVI vs MS;  c TAVI vs SAVR
Abbreviations: see TABLE 1
TABLE 4 Complications after the procedure
Variable TAVI (n = 39) MT (n = 50) MS (n = 44) SAVR (n = 40) P value
complications in total 35.9 10 13.6 45 0.0002
conduction disturbances 23.1 2 4.6 10 0.004
new LBBB 7.9 0 0 0 0.01
new third-degree AV block 10.5 0 0 2.5 0.01
arrhythmias 18 0 2.3 10.3 0.004
new AF 7.7 0 0 2.5 0.07
retoracotomy 0 2 0 2.5 0.6
hydrothorax 10.3 2 6.8 17.5 0.07
pneumothorax 5.1 4 0 5 0.5
cardiac tamponade 7.7 2 0 0 0.07
paravalvular leak 2.6 0 0 0 0.3
local complication 2.6 0 0 2.5 0.5
hemodialysis 0 0 0 2.5 0.3
implanted valve regurgitation 0 0 0 2.5 0.3
pulmonary edema 2.6 0 0 0 0.3
bleeding 2.6 0 0 0 0.3
drainage, ml 87.9 ±485 450.9 ±343.9 397 ±229.2 829.2 ±787.4 0.0001
intra-aortic balloon contrapulsation 2.6 0 0 0 0.3
stroke/TIA 0 0 0 0 – 
MI/cardiogenic shock 0 0 0 0 – 
catecholamines 29 96.7 85.7 87.5 0.00001
Data are presented as percentage of patients or mean ± standard deviation.
Abbreviations: AF, atrial fibrillation; AV, atrioventricular block; LBBB, left bundle branch block; MI, myocardial infarction; TIA, transient ischemic 
attack; others, see TABLE 1
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40.3 ±12.5 37.8 ±12.8
FIGURE 1  
Echocardiography results: 
A – EF before the 
procedure (P = 0.2); 
B – EF after the 
procedure (P = 0.01);  
C – EF 1 week after the 
procedure (P = 0.001) 
Abbreviations:  
EF, ejection fraction; 
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demonstrated that TAVI is associated with im-
proved outcomes in this inoperable population.4 
TAVI is associated with a high possibility of ma jor 
vascular complications, cerebrovascular events, or 
significant prosthetic valve aortic regurgitation 
(AR).17 One serious bleeding complication after 
TAVI was reported in our study. The incidence of 
major vascular complications varies from 10.7% to 
33.3% and depends on the access site, the clinical 
profile of the treated patients, and the size of the 
introducer sheaths.4 A recent study demonstrat-
ed that during TAVI embolic debris are liberated 
from the native aortic valve and aorta and travel 
to cerebral circulation.20 Most of the patients with 
new ischemic defects are asymptomatic; never-
theless, the incidence of stroke after TAVI reach-
es 6.7%.19 In our study, neither stroke nor tran-
sient ischemic attack occurred. A severely stenot-
ic and calcified aortic valve, the use of large de-
livery systems, and multiple manipulations dur-
ing device implantation (ie, balloon postdilation 
and device repositioning) have been associated 
with an increased risk of debris embolization.4
New-onset atrial fibrillation (NOAF) may also 
promote embolus formation and embolization. 
The effectiveness of cerebral embolic protection 
devices in decreasing the risk of stroke has not 
been proved so far. NOAF is a frequent complica-
tion associated with TAVI with about half of the 
AF episodes occurring within 24 hours and more 
than 80%—within the first 3 days after the pro-
cedure.21 NOAF is associated with an increased 
rate of cardioembolic events following the proce-
dure. Amat-Santos et al21 reported an incidence 
of NOAF reaching 31% of the patients with no 
prior chronic/paroxysmal AF, undergoing TAVI 
with a balloon-expandable valve by transfemoral 
or transapical approach. In PARTNER Cohort A, 
the incidence of NOAF within 30 days was 15% in 
patients with no prior AF.21 Two-thirds of the pa-
tients included in the PARTNER trial underwent 
the procedure by transfemoral approach. The rate 
of NOAF was close to the rate of 16% observed 
by  Amat-Santos et al21 in a cohort of patients 
undergoing transfemoral TAVI. In our study, the 
incidence of NOAF after TAVI was 7.7%, with no 
statistical differences between the groups. After 
the propensity score match, no differences were 
found between TAVI and other groups (TAVI vs 
minithoracotomy, P = 0.08; TAVI vs ministernot-
omy, P = 0.08; TAVI vs SAVR, P = 0.3).
Older age, the use of the Medtronic CoreValve 
revalving system, the presence of right bundle 
branch block, a low placement of the prosthesis, 
a porcelain aorta, and valve oversizing are associ-
ated with conduction disorders that require pace-
maker implantation.4 There is evidence that con-
duction disorders have a negative effect on sys-
tolic LV function and on the patient’s function-
al status.4 A recent study demonstrated an inci-
dence of new conduction disturbances after TAVI 
of up to 43%, the most common (35%) being the 
left bundle branch block (LBBB).22 Other studies 
reported a similar incidence or higher.23,24 A few 
There are no data comparing all 4 types of AVR. 
The PARTNER Cohort B study demonstrated that 
patients treated with TAVI had a lower mortali-
ty rate compared with those receiving standard 
medical therapy (medications or medications and 
balloon aortic valvuloplasty)—30.7% vs 50.7% 
(P <0.001).15 The available data on TAVI versus 
SAVR for patients at a higher surgical risk show 
similar outcomes for both groups.16 Previous pub-
lications reported that a 30-day mortality rate af-
ter TAVI ranged from 3.2% to 15.2%.17 Our study 
showed a similar rate of all-cause mortality at 30 
days in the TAVI group. In addition, no signifi-
cant differences were observed between TAVI and 
surgical treatment options in terms of mortali-
ty at any time point of the follow-up. No signifi-
cant differences between TAVI, minithoracotomy, 
ministernotomy, and SAVR were found in terms 
of mortality after the propensity score match. 
The similar mortality rates for TAVI and surgi-
cal treatment options could be due to an evolv-
ing device profile, appropriate patient selection 
by an experienced heart team, skillful operators, 
or the minimal invasiveness of TAVI.17 
In the ADVANCE trial,18 the all-cause mor-
tality rates were low both at 30 days (4.5%) and 
at 12 months (17.9%).19 The procedural success 
rate in the ADVANCE study was 97.8%, and the 
overall complication rate at 30 days was low.19 In 
our study, patients treated with TAVI had a sig-
nificantly higher total rate of complications af-
ter the procedure in comparison with the oth-
er groups. We also observed a higher risk of con-
duction disturbances and arrhythmias after the 
procedure. After the propensity score match, sig-
nificant differences between TAVI, minithoracot-
omy, and ministernotomy were found in terms 
of complications, arrhythmias, and conduction 
disturbances after the procedure (TAVI vs mini-
thoracotomy: 35.9% vs 10.3%, P = 0.007; 18% vs 
0%, P = 0.005; 23.1% vs 2.6%, P = 0.007; respec-
tively; TAVI vs ministernotomy: 35.9% vs 15.4%, 
P = 0.004; 18% vs 2.6%; P = 0.02, 23.1% vs 5.3%, 
P = 0.03; respectively). There were no significant 
differences in terms of the above complications 
between TAVI and SAVR (P = 0.5, P = 0.3, and P 
= 0.06, respectively). 
An improvement in the NYHA class 1 week af-
ter the procedure was also comparable with the 
results at 30 days in the ADVANCE study. The 
1-year mortality rates in our study compared fa-
vorably with the 1-year all-cause mortality rate 
of 24.2% in TAVI patients in the PARTNER trial 
(cohort A) and with the mortality rate of 18.9% 
in the transfemoral TAVI subgroup using the Ed-
wards SAPIEN valve in the SOURCE registry.6 
These results might have been caused by the dif-
ferences in the baseline risk level of our patients 
in comparison with the PARTNER trial (cohort 
A) and the SOURCE registry.
The recently reported CoreValve US Pivotal 
study, which included 471 high-risk patients im-
planted with the CoreValve prosthesis (Medtron-
ic Inc, Minneapolis, Minnesota, United States), 
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studies regarding TAVI with the CoreValve pros-
thesis did not demonstrate a significant improve-
ment in LVEF after the implantation.28 The differ-
ent rates of conduction disturbances, in particu-
lar LBBB, could possibly explain the differences 
in  LVEF after TAVI using Edwards SAPIEN ver-
sus TAVI using CoreValve implants. 
In our study, no significant differences in EF 
before AVR were observed between the groups 
(P = 0.2). LVEF was significantly higher in TAVI 
patients after the procedure and 1 week after the 
procedure in comparison with patients undergo-
ing  SAVR, ministernotomy, and minithoracoto-
my (FIGURE 1). Significant differences between TAVI 
and surgical approaches in terms of EF assessed 
1 week after the procedure were maintained even 
after the propensity score match (TABLE 5). Patients 
allocated to TAVI showed a significantly smaller 
decrease in the mean value of LVEF before AVR, 
after AVR, and 1 week after AVR in comparison 
with the other treatment options. 
Moderate or severe paravalvular AR after TAVI 
is reported in around 15%.4 Published data have 
shown that moderate or severe AR after TAVI is 
associated with worse outcomes and is an inde-
pendent predictor of mortality.4 In the PARTNER 
study, the presence of mild AR was associated 
with worse prognosis.4 In our study, paravalvu-
lar AR was observed only in 1 patient. Myocardial 
injury (MI), defined as an elevated troponin level 
greater than 20 times the 99th percentile in pa-
tients with normal baseline levels is observed in 
most patients undergoing TAVI.29 A recent study 
demonstrated an association between increased 
series of 10 to 102 patients described new pace-
maker implantation due to new-onset complete 
heart block (NOCHB) in 27% to 33% of the pa-
tients undergoing TAVI with CoreValve implan-
tation and in 4% to 12%—with Edwards SAPIEN 
implantation.25 A recently published analysis of 
200 patients reported new pacemaker implanta-
tion due to NOCHB in 22% of the particpants.25 
Following SAVR, new-onset bundle branch block 
was reported in 16% to 32% of the patients and 
the need for permanent pacemakers—in 3% to 
8% of the patients.26 In our study, we reported a 
significantly higher risk of new LBBB and third-
-degree atrioventricular (AV) block in patients un-
dergoing TAVI (TABLE 4). No significant differenc-
es in the risk of new LBBB were found between 
TAVI and surgical methods after the propensity 
score match (TAVI vs minithoracotomy, P = 0.08; 
TAVI vs ministernotomy, P = 0.08; TAVI vs SAVR 
P = 0.3). The rates of new third-degree AV block in 
TAVI as compared with surgical methods after the 
propensity score match are presented in TABLE 5. 
TAVI seems to reduce LV afterload, increase 
LVEF, and promote LV remodeling. These chang-
es have a beneficial effect on mitral valve perfor-
mance. Several reports have shown a decrease in 
the severity of mitral regurgitation after TAVI.4 In 
a study comparing LV function between patients 
undergoing transcatheter and surgical valve im-
plantation, patients undergoing TAVI showed a 
better recovery of LVEF at 1 year.27 In our analy-
sis, as well as others that reported improvement 
in LVEF after TAVI, the Edwards SAPIEN valve 
was used for the procedure.27 On the other hand, 
TABLE 5 Complications after the procedure and clinical outcomes after the propensity score match in the study groups
Variable TAVI (n = 39) MT (n = 50) MS (n = 44) SAVR (n = 40) P valuea P valueb P valuec
new third-degree AV block 13 0 0 2.6 0.02 0.02 0.08
catecholamines 29 96.7 86.5 89.7 0.00001 0.00001 0.00001
EF at 1 week, % 50.2 ±13.1 42 ±12 37.6 ±13.1 40.9 ±12.2 0.003 0.0005 0.003
CKMB, U/l 37 ±25 99.6 ±208 42 ±13.5 80.6 ±77.2 0.17 0.006 0.00001
troponin T, ng/ml 0.4 ±0.3 0.7 ±1 0.5 ±0.3 0.9 ±0.6 0.54 0.35 0.00006
Data are presented as mean ± standard deviation or percentage.
P value is adjusted for propensity match score.
a TAVI vs MT;  b TAVI vs MS;  c TAVI vs SAVR
Abbreviations: CKMB, creatine kinase-MB; others, see TABLE 1, TABLE 4, and FIGURE 1
TABLE 6 Laboratory results at baseline and after the procedure
Variable TAVI (n = 39) MT (n = 50) MS (n = 44) SAVR (n = 40) P value
postprocedural CKMB, U/l 30 (22–37) 30 (24–81) 44 (35–56) 79 (41–76) 0.00001
postprocedural troponin T, ng/ml 0.4 (0.3–0.5) 0.3 (0.2–0.6) 0.4 (0.3–0.7) 0.9 (0.5–1) 0.00001
Hb at baseline, g/dl 12 ±2.1 11 ±1.7 12.6 ±1.8 13.6 ±1.4 0.00001
postprocedural Hb, g/dl 10 ±1.4 10.4 ±1.5 10.4 ±1.1 11.1 ±1.4 0.008
Data are presented as mean ± standard deviation or median (interquartile range).
Abbreviations: Hb, hemoglobin; others, see TABLES 1 and 2
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comorbidities). The available results indicate that 
TAVI is an acceptable alternative to surgery in se-
lected high-risk patients. Further studies focus-
ing on how to lower the rates of common com-
plications are needed.
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WPROWADZENIE Przezskórna implantacja zastawki aortalnej (transcatheter aortic valve implantation – 
TAVI) i minimalnie inwazyjna wymiana zastawki aortalnej (minitorakotomia i ministernotomia) stały się 
wartościową alternatywą dla klasycznej kardiochirurgicznej operacji u pacjentów obciążonych wysokim 
ryzykiem z ciężką objawową stenozą aortalną (aortic stenosis – AS).
CELE Celem pracy była ocena długoterminowych wyników i powikłań u pacjentów z objawową AS 
i leczonych za pomocą TAVI, operacyjnej wymiany zastawki aortalnej (surgical aortic valve replacement 
– SAVR), minitorakotomii lub ministernotomii.
PACJENCI I METODY 173 pacjentów z objawową AS zostało włączonych do badania w latach 2011–2013. 
Wskaźnik skłonności (ang. propensity score) został policzony osobno dla TAVI i każdej metody kardiochirur-
gicznej. Różnice w wynikach klinicznych pacjentów po TAVI w porównaniu z metodami chirurgicznymi 
zostały dostosowane do wskaźnika skłonności za pomocą analizy regresji logistycznej i zaprezentowane 
jako skorygowany iloraz szans z 95% przedziałem ufności.
WYNIKI Średnia długość obserwacji pacjentów wyniosła 583,5 dni (przedział międzykwartylowy: 
298–736 dni). Przed wymianą zastawki aortalnej (aortic valve replacement – AVR) nie znaleziono istot-
nych statystycznie różnic między grupami w zakresie frakcji wyrzutowej (ejection fraction – EF). Tydzień 
po AVR stwierdzono istotnie statystycznie wyższą średnią wartość EF u pacjentów po TAVI w porów-
naniu z pozostałymi grupami (TAVI: 50,2% ±13,1%; minitorakotomia: 44,1% ±13,4%; minsternotomia: 
37,8% ±12,8%; SAVR: 40,3% ±12,5%; p = 0,001). Nie stwierdzono różnic między grupami w zakresie 
śmiertelności w ciągu całego okresu obserwacji (p = 0,8). Według naszej wiedzy nasze badanie jako 
pierwsze porównało TAVI z minitorakotomią, ministernotomią i SAVR pod względem wyników odległych, 
takich jak śmiertelność w najdłuższym dostępnym okresie obeserwacji, funkcja skurczowa lewej komory, 
powikłania po zabiegu oraz zaburzenia przewodnictwa i rytmu po zabiegu.
WNIOSKI Pacjenci po TAVI mają korzystniejsze wyniki leczenia w porównaniu z minitorakotomią, 
ministernotomią i SAVR. Nie stwierdzono różnic między grupami w zakresie śmiertelności w ciągu 
całego okresu obserwacji. TAVI ma korzystniejszy wpływ na poprawę funkcji lewej komory i wzrost EF 
w porównaniu z metodami chirurgicznymi.
ARTYKUŁ ORYGINALNY
Wyniki odległe po chirugicznej i przezskórnej 
wymianie zastawki aortalnej
Tomasz Tokarek1, Robert Sobczyński2, Artur Dziewierz3, Zbigniew Siudak1, 
Wojciech Zasada3, Danuta Sorysz3, Roman Pfitzner2, Jerzy Sadowski2, 
Grzegorz Dębski4, Ewa Dziewięcka1, Krystian Gruszka1, Dariusz Dudek1
1  Klinika Kardiologii Interwencyjnej, Instytut Kardiologii, Uniwersytet Jagielloński, Collegium Medicum, Kraków
2  Klinika Chirurgii Serca, Naczyń i Transplantologii, Instytut Kardiologii, Uniwersytet Jagielloński, Collegium Medicum, Kraków 
3  II Klinika Kardiologii, Uniwersytet Jagielloński, Collegium Medicum, Kraków
4  Oddział Kardiologii, Szpital Specjalistyczny im. Józefa Dietla, Kraków
